Table 5: Open in new tab Univariable...

	Univariable analysis
Age
61>/61≤	1.882	1.307–2.710	0.001	1.778	1.195–2.645	0.005
Gender
Female/male	1.147	0.753–1.746	0.524	1.122	0.566–2.226	0.742
FEV1 (ml)
2372 ≤/2372 >	1.335	0.937–1.902	0.110	1.349	0.910–1.998	0.136
FEV1 (%)
84 ≤/84 >	1.598	1.123–2.274	0.009	1.271	0.849–1.904	0.244
Smoking history
Present/absent	1.135	0.727–1.773	0.577	1.170	0.640–2.140	0.610
Location
Left/right	1.027	0.859–1.228	0.769	1.078	0.878–1.325	0.473
Neoadjuvant therapy
Absent/present	1.462	1.001–2.135	0.050	1.261	0.806–1.972	0.309
Histopathological analysis
Adenocarcinoma/SCC	1.147	0.807–1.630	0.445	1.097	0.678–1.773	0.706
T status
T3–4/T1–2	1.383	0.970–1.971	0.073	1.067	0.699–1.630	0.763
N1	1.060	0.688–1.631	0.792	1.415	0.933–2.145	0.102
N2	1.925	1.152–3.216	0.012	2.635	1.412–4.916	0.002
Pathological stage
Stage III–IV/stage I–II	1.589	1.110–2.276	0.011	1.922	1.280–2.888	0.002
Prognostic factor
Present/absent	1.477	0.952–2.289	0.082	1.269	0.808–1.995	0.301
Stromal infiltration
Present/absent	1.069	0.749–1.526	0.712	1.038	0.697–1.546	0.853
Lymphatic invasion
Present/absent	1.470	1.034–2.091	0.032	1.050	0.709–1.557	0.806
Vascular invasion
Present/absent	1.318	0.910–1.909	0.144	1.290	0.808–2.061	0.286
Perineural invasion
Present/absent	1.675	1.065–2.635	0.026	1.993	1.271–3.124	0.003

Univariable analysis

Standard lobectomy

Sleeve lobectomy

Variables

95% CI (lower–upper)

P-value

95% CI (lower–upper)

P-value

Age

61>/61≤

1.882

1.307–2.710

0.001

1.778

1.195–2.645

0.005

Gender

Female/male

1.147

0.753–1.746

0.524

1.122

0.566–2.226

0.742

FEV1 (ml)

2372 ≤/2372 >

1.335

0.937–1.902

0.110

1.349

0.910–1.998

0.136

FEV1 (%)

84 ≤/84 >

1.598

1.123–2.274

0.009

1.271

0.849–1.904

0.244

Smoking history

Present/absent

1.135

0.727–1.773

0.577

1.170

0.640–2.140

0.610

Location

Left/right

1.027

0.859–1.228

0.769

1.078

0.878–1.325

0.473

Neoadjuvant therapy

Absent/present

1.462

1.001–2.135

0.050

1.261

0.806–1.972

0.309

Histopathological analysis

Adenocarcinoma/SCC

1.147

0.807–1.630

0.445

1.097

0.678–1.773

0.706

T status

T3–4/T1–2

1.383

0.970–1.971

0.073

1.067

0.699–1.630

0.763

1.060

0.688–1.631

0.792

1.415

0.933–2.145

0.102

1.925

1.152–3.216

0.012

2.635

1.412–4.916

0.002

Pathological stage

Stage III–IV/stage I–II

1.589

1.110–2.276

0.011

1.922

1.280–2.888

0.002

Prognostic factor

Present/absent

1.477

0.952–2.289

0.082

1.269

0.808–1.995

0.301

Stromal infiltration

Present/absent

1.069

0.749–1.526

0.712

1.038

0.697–1.546

0.853

Lymphatic invasion

Present/absent

1.470

1.034–2.091

0.032

1.050

0.709–1.557

0.806

Vascular invasion

Present/absent

1.318

0.910–1.909

0.144

1.290

0.808–2.061

0.286

Perineural invasion

Present/absent

1.675

1.065–2.635

0.026

1.993

1.271–3.124

0.003

	Univariable analysis
Age
61>/61≤	1.882	1.307–2.710	0.001	1.778	1.195–2.645	0.005
Gender
Female/male	1.147	0.753–1.746	0.524	1.122	0.566–2.226	0.742
FEV1 (ml)
2372 ≤/2372 >	1.335	0.937–1.902	0.110	1.349	0.910–1.998	0.136
FEV1 (%)
84 ≤/84 >	1.598	1.123–2.274	0.009	1.271	0.849–1.904	0.244
Smoking history
Present/absent	1.135	0.727–1.773	0.577	1.170	0.640–2.140	0.610
Location
Left/right	1.027	0.859–1.228	0.769	1.078	0.878–1.325	0.473
Neoadjuvant therapy
Absent/present	1.462	1.001–2.135	0.050	1.261	0.806–1.972	0.309
Histopathological analysis
Adenocarcinoma/SCC	1.147	0.807–1.630	0.445	1.097	0.678–1.773	0.706
T status
T3–4/T1–2	1.383	0.970–1.971	0.073	1.067	0.699–1.630	0.763
N1	1.060	0.688–1.631	0.792	1.415	0.933–2.145	0.102
N2	1.925	1.152–3.216	0.012	2.635	1.412–4.916	0.002
Pathological stage
Stage III–IV/stage I–II	1.589	1.110–2.276	0.011	1.922	1.280–2.888	0.002
Prognostic factor
Present/absent	1.477	0.952–2.289	0.082	1.269	0.808–1.995	0.301
Stromal infiltration
Present/absent	1.069	0.749–1.526	0.712	1.038	0.697–1.546	0.853
Lymphatic invasion
Present/absent	1.470	1.034–2.091	0.032	1.050	0.709–1.557	0.806
Vascular invasion
Present/absent	1.318	0.910–1.909	0.144	1.290	0.808–2.061	0.286
Perineural invasion
Present/absent	1.675	1.065–2.635	0.026	1.993	1.271–3.124	0.003

Table 5:

Open in new tab

Univariable prognostic factor analysis with Cox-regression in the standard and sleeve lobectomy groups

	Univariable analysis
	Standard lobectomy			Sleeve lobectomy
Variables	HR	95% CI (lower–upper)	P-value	HR	95% CI (lower–upper)	P-value
Age
61>/61≤	1.882	1.307–2.710	0.001	1.778	1.195–2.645	0.005
Gender
Female/male	1.147	0.753–1.746	0.524	1.122	0.566–2.226	0.742
FEV1 (ml)
2372 ≤/2372 >	1.335	0.937–1.902	0.110	1.349	0.910–1.998	0.136
FEV1 (%)
84 ≤/84 >	1.598	1.123–2.274	0.009	1.271	0.849–1.904	0.244
Smoking history
Present/absent	1.135	0.727–1.773	0.577	1.170	0.640–2.140	0.610
Location
Left/right	1.027	0.859–1.228	0.769	1.078	0.878–1.325	0.473
Neoadjuvant therapy
Absent/present	1.462	1.001–2.135	0.050	1.261	0.806–1.972	0.309
Histopathological analysis
Adenocarcinoma/SCC	1.147	0.807–1.630	0.445	1.097	0.678–1.773	0.706
T status
T3–4/T1–2	1.383	0.970–1.971	0.073	1.067	0.699–1.630	0.763
N1	1.060	0.688–1.631	0.792	1.415	0.933–2.145	0.102
N2	1.925	1.152–3.216	0.012	2.635	1.412–4.916	0.002
Pathological stage
Stage III–IV/stage I–II	1.589	1.110–2.276	0.011	1.922	1.280–2.888	0.002
Prognostic factor
Present/absent	1.477	0.952–2.289	0.082	1.269	0.808–1.995	0.301
Stromal infiltration
Present/absent	1.069	0.749–1.526	0.712	1.038	0.697–1.546	0.853
Lymphatic invasion
Present/absent	1.470	1.034–2.091	0.032	1.050	0.709–1.557	0.806
Vascular invasion
Present/absent	1.318	0.910–1.909	0.144	1.290	0.808–2.061	0.286
Perineural invasion
Present/absent	1.675	1.065–2.635	0.026	1.993	1.271–3.124	0.003

	Univariable analysis
	Standard lobectomy			Sleeve lobectomy
Variables	HR	95% CI (lower–upper)	P-value	HR	95% CI (lower–upper)	P-value
Age
61>/61≤	1.882	1.307–2.710	0.001	1.778	1.195–2.645	0.005
Gender
Female/male	1.147	0.753–1.746	0.524	1.122	0.566–2.226	0.742
FEV1 (ml)
2372 ≤/2372 >	1.335	0.937–1.902	0.110	1.349	0.910–1.998	0.136
FEV1 (%)
84 ≤/84 >	1.598	1.123–2.274	0.009	1.271	0.849–1.904	0.244
Smoking history
Present/absent	1.135	0.727–1.773	0.577	1.170	0.640–2.140	0.610
Location
Left/right	1.027	0.859–1.228	0.769	1.078	0.878–1.325	0.473
Neoadjuvant therapy
Absent/present	1.462	1.001–2.135	0.050	1.261	0.806–1.972	0.309
Histopathological analysis
Adenocarcinoma/SCC	1.147	0.807–1.630	0.445	1.097	0.678–1.773	0.706
T status
T3–4/T1–2	1.383	0.970–1.971	0.073	1.067	0.699–1.630	0.763
N1	1.060	0.688–1.631	0.792	1.415	0.933–2.145	0.102
N2	1.925	1.152–3.216	0.012	2.635	1.412–4.916	0.002
Pathological stage
Stage III–IV/stage I–II	1.589	1.110–2.276	0.011	1.922	1.280–2.888	0.002
Prognostic factor
Present/absent	1.477	0.952–2.289	0.082	1.269	0.808–1.995	0.301
Stromal infiltration
Present/absent	1.069	0.749–1.526	0.712	1.038	0.697–1.546	0.853
Lymphatic invasion
Present/absent	1.470	1.034–2.091	0.032	1.050	0.709–1.557	0.806
Vascular invasion
Present/absent	1.318	0.910–1.909	0.144	1.290	0.808–2.061	0.286
Perineural invasion
Present/absent	1.675	1.065–2.635	0.026	1.993	1.271–3.124	0.003

CI: confidence interval; FEV1: forced expiratory volume in 1 s; N: node; SCC: squamous cell carcinoma.

Values with P < 0.05 have been bolded.

This Feature Is Available To Subscribers Only